King's Research Portal

DOI:

[10.1007/s12185-017-2231-3](https://doi.org/10.1007/s12185-017-2231-3)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Upanan, S., McKie, A., Latunde-Dada, G., Roytrakul, S., Uthaipibull, C., Pothacharoen, P., Kongtawelert, P., Fucharoen, S., & Srichairatanakool, S. (2017). Hepcidin suppression in -thalassemia is associated with the down-regulation of atonal homolog 8. *International Journal of Hematology*, 196–205.
<https://doi.org/10.1007/s12185-017-2231-3>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

1 **RESEARCH ARTICLE**

2
3 **Atoh8: a transcriptional regulator of *HAMP* is down-regulated in HuH7 cells**
4 **cultured in the β -thalassemia patient sera and β -thalassemic mice**
5

6 Supranee Upanan¹, Andrew T. McKie², Gladys O. Latunde-Dada², Chairat Uthaipibull³, Suthat
7 Fucharoen⁴, Somdet Srichairatanakool^{1*}
8

9 *¹Department of Biochemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200 Thailand*

10 *²Division of Diabetes and Nutritional Sciences, King's College London, London, SE1 9NH, United*
11 *Kingdom*

12 *³National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology*
13 *Development Agency (NSTDA), Science Park, Pathumthani 12120 Thailand*

14 *⁴Thalassemia Research Center, Institute of Molecular Biosciences, Mahidol University Salaya Campus,*
15 *Nakornpathom 73170 Thailand*
16
17

18 **KEY WORDS:** Atoh8, *HAMP*, Thalassemia, Iron overload, erythropoiesis
19
20
21

ABSTRACT

Objective: This study aimed to demonstrate the down-regulation of *Atoh8* relating to hepcidin suppression in β -thalassemia. **Methods:** HuH7 cells were cultured in DMEM medium supplemented with 20% β -thalassemia patient sera (HbE/ β -thalassemia and β -thalassemia major) or normal serum as a control. To investigate the effect of *Atoh8* on *HAMP* transcription in β -thalassemia, HEK293 cells were transfected with ATOH8-FLAG expression plasmid and cultured in DMEM medium supplemented with 20% β -thalassemia patient sera. *Atoh8* and *HAMP* mRNA expression were analyzed by qPCR, and *HAMP* promoter activity was detected by the luciferase reporter assay. In addition, hepatic *Atoh8* and *Hamp1* mRNA expression in β -thalassemic mice were also determined. **Results:** In the cultured HuH7 cells, *HAMP* mRNA levels and *HAMP* promoter activity in all β -thalassemia serum groups were significantly lower than the normal serum group. Interestingly, our study found that *Atoh8* expression was down-regulated in the same direction as *HAMP* expression being suppressed despite iron overload. The *Atoh8* transfection could enhance *HAMP* expression in endogenous *HAMP* mRNA levels as well as *HAMP* promoter activity in HEK293 cells cultured in the β -thalassemia patient sera. In accordance with this, hepatic *Atoh8* and *Hamp1* mRNA expression in β -thalassemic mice were also down-regulated. **Conclusion:** It's likely that the increased erythropoietic activity in β -thalassemia would suppress *Atoh8* expression, subsequently down-regulating hepcidin expression. Therefore, *Atoh8* would be a novel regulator of *HAMP* transcription in the β -thalassemia.

*Corresponding author: Somdet Srichairattanakool, Department of Biochemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.

Tel: +66 53 945322

Fax: +66 53 894031

E-mail: ssrichai@med.cmu.ac.th

Financial support: The Royal Golden Jubilee PhD Program, Thailand Research Fund (Grant No. PHD/0345/2552) and Faculty of Medicine Research Fund, Chiang Mai University Thailand

Acknowledgements

The authors thank for the Royal Golden Jubilee PhD. Program, Thailand Research Fund, and the Faculty of Medicine Research Fund, Chiang Mai University, Thailand. Most of work was undertaken in the laboratory of iron metabolism research group of Prof. Andrew T. McKie and Dr. Gladys Oluyemisi Latunde-Dada, Division of Diabetes and Nutritional Sciences, King's College London, United Kingdom. Thank Dr. Neeta Patel for providing the *HAMP* promoter plasmid and ATOH8-FLAG expression plasmid. The work was partially supported by the Chair Professor Grant of National Science and Technology Development Agency through Professor Suthat Fucharoen, MD., and the Thalassemia Research Center, Mahidol University, Salaya Campus, Nakornpathom, Thailand. We thank FWB Genomics Centre King's College London, United Kingdom as well as the Medical Science Research Equipment Centre, Faculty of Medicine, Chiang Mai University, Thailand for supplying the research equipment.

1. Introduction

Hepcidin, an iron regulatory hormone, is a 25-amino acid peptide produced by hepatocytes in the liver (1-6). It plays a critical role in the balance of systemic iron homeostasis by inducing the internalization and degradation of the iron- exporter ferroportin on enterocytes, hepatocytes and macrophages (7-11). Thus the increase of hepcidin inhibits duodenal iron absorption and iron release from hepatocytes and macrophages. This can limit iron overload; however, urinary and serum hepcidin levels in β -thalassemia are reduced (12-15) leading to increased iron absorption which exacerbates iron overload condition.

Hepatic hepcidin (*HAMP*) mRNA expression is regulated in by three major stimuli including iron levels, inflammation and erythropoietic activity via different signal transduction pathways. The regulation of *HAMP* transcription responds to changes of tissue iron through the bone morphogenetic protein (BMP) signaling pathway and a change of hepatic BMP6 levels (16, 17). The *HAMP* transcription is activated by the inflammation via STAT-3 signaling pathway (18). The signal transduction pathway to regulate *HAMP* transcription under the erythropoietic activity remains unclear. Two molecules produced by erythroid precursors, the growth differentiation factor 15 (GDF15) and the twisted gastrulation factor 1 (TWSG1), and the bone morphogenetic protein binding endothelial cell precursor-derived regulator (BMPER) produced by endothelial cells have been reported as the negative regulator of *HAMP* transcription by BMP signaling pathway (19-22). In addition, a recent study suggested that erythroferrone (ERFE), produced by erythroid precursors, acts as a new erythroid-derived hormone and inhibits hepcidin expression during stress erythropoiesis (23). In β -thalassemia studies, Tanno et al demonstrated that GDF15 levels were elevated in β -thalassemia patient serum with low hepcidin and that GDF15 suppressed hepcidin mRNA expression in human hepatocyte cultures (19). In contrast, Casanovas et al

1 reported that the hepcidin expression was suppressed in Gdf-15^{-/-} mice subjected to phlebotomy
2 and that bone marrow GDF15 were not increased in the β -thalassemic mice (24). Therefore, the
3 relationship between GDF15 and hepcidin regulation remains controversial. TWSG1 interfered
4 with BMP-mediated hepcidin expression in human hepatocyte cultures and was up-regulated in
5 the β -thalassemic mice (20). ERFE mRNA expression was increased in the β -thalassemic mice,
6 and hepcidin suppression in ERFE-deficient mice was failed after hemorrhage (23). However,
7 human correlative studies of TWSG1 and ERFE have not been investigated yet.

8 Recently, Patel et al (25) has identified Atoh8, atonal homolog 8 (Drosophila), as a novel
9 positive regulator of *HAMP* transcription via two independent mechanisms: E-box dependent
10 transcriptional activation; and the increase of cellular pSMAD1,5,8 levels in BMP signaling
11 pathway. In addition, the down-regulation of Atoh8 was observed in mice with increased
12 erythropoietic activity, which appears to override the activation of Atoh8 by the increased iron
13 levels. All of these explain how hepcidin suppression was carried on by increased erythropoietic
14 activity in the conditions of liver iron loading and increased BMP6 levels without any change in
15 pSMAD1,5,8 levels (26). Given that the increased erythropoiesis activity suppressed Atoh8
16 expression similar to hepcidin expression we hypothesized that Atoh8 may be a novel candidate
17 transcriptional regulator of *HAMP* in the β -thalassemia.

18 19 **2. Materials and Methods**

20 ***2.1. β -Thalassemia serum samples***

21 10-18 years old male (N=11) and female (N=12) HbE/ β -thalassemia patients (HbE/T-Male
22 and HbE/T-Female) and male (N=9) and female (N=6) β -thalassemia major patients (TM-Male
23 and TM-Female) from Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand were the

volunteers for this research. The β -thalassemia patients are usually treated with iron chelator(s) (DFP, DFO or DFX) and regularly receive blood transfusion. The experimental protocol was conducted with the approval of the Research Ethics Committee, Faculty of Medicine, Chiang Mai University, Thailand (Research ID: 2151/ Study Code: BIO-2556-02151). Their bloods were collected monthly for 3 months before they receive the blood transfusion. The bloods were collected into 5-ml vacuum tubes, left to clot at room temperature for 30 minutes and centrifuged at 3,000g for 10 minutes. The sera were collected and stored at -20°C until use. All sera in the same group were pooled together and blood iron parameters were determined. Serum Iron (SI) and Total Iron Binding Capacity (TIBC) were analyzed by Clinical Chemistry Laboratory, Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand. Non-transferrin bound iron (NTBI) concentrations were measured by using NTA chelation/HPLC method (27). Serum ferritin levels were analyzed by Tumor Marker Laboratory, Faculty of Medicine, Chiang Mai University, Thailand. Serum hepcidin levels were estimated by using Hepcidin (Hepc) ELISA Kit (CEB979Hu, Uscn Life Science Inc., Hubei, China).

2.2. Cell culture and cell transfection

2.2.1. Cell culture

Human hepatoma cell lines (HuH7) or human embryonic kidney 293 cell lines (HEK293) were cultured in DMEM medium supplemented with 10% (v/v) fetal bovine serum (FBS), 2 mM L-glutamine and 1% penicillin-streptomycin and incubated at 37°C under a humidified 5% CO₂ atmospheric condition.

The conditions for culturing cells in human sera were determined to imitate β -thalassemia patients as previously described (28). 24-hour (60% confluent) grown cells were starved in serum-free DMEM medium supplemented with 1% penicillin-streptomycin for 24 hours as a starvation

step. Subsequently, the medium was removed and the cells were grown in DMEM medium supplemented with 20% human sera [Normal (Invitrogen, UK), male HbE/ β -thalassemia, female HbE/ β -thalassemia, male β -thalassemia major and female β -thalassemia major], 2 mM L-glutamine and 1% penicillin-streptomycin for 24 hours. *HAMP* and *Atoh8* mRNA expression were analyzed by qPCR.

2.2.2. Cell transfection

2.2.2.1. *HAMP* promoter transfection in HuH7 cells

To confirm endogenous *HAMP* mRNA levels from qPCR result, the *HAMP* promoter assay was performed. Before the cells were grown in DMEM medium supplemented with human sera, *HAMP* reporter plasmid was co-transfected with a TK-renilla control reporter plasmid at a 1:4 ratio in serum-free DMEM medium supplemented with 1% penicillin-streptomycin into the HuH7 cells for 24 hours in the starvation step as mentioned above by using Fugene 6 (Promega, UK) according to the manufacturer's instructions (29). After the transfected cells were grown in DMEM medium supplemented with human sera, *HAMP* promoter activity was detected by luciferase reporter assay.

2.2.2.2. *Atoh8* and *HAMP* promoter transfection in HEK293 cells

To study the effect of *Atoh8* on *HAMP* transcription, HEK293 cells, known as the model for *Atoh8* transfection as the previous study (25), were transfected with ATOH8-FLAG expression plasmid or empty plasmid (Origen vector) in serum-free DMEM medium supplemented with 1% penicillin-streptomycin for 6 hours in the starvation step as mentioned above by using Fugene 6. After the transfected cells were grown in DMEM medium supplemented with human sera, *Atoh8* mRNA and *HAMP* mRNA expression were determined by qPCR.

For *HAMP* promoter assay, *HAMP* reporter plasmid was co-transfected with a TK-renilla control reporter plasmid (1:4 ratio) and ATOH8-FLAG expression plasmid in serum-free DMEM

medium supplemented with 1% penicillin-streptomycin into the HEK293 cells for 6 hours in the starvation step by using Fugene 6 (25). After the transfected cells were grown in DMEM medium supplemented with human sera, *HAMP* promoter activity was detected by the luciferase reporter assay.

2.3. Animals

7-8 months old male (N=5) and female (N=5) C57/BL6, wild type (WT, $\mu\beta^{+/+}$) and heterozygous β -globin knockout (BKO, $\mu\beta^{\text{th-3/+}}$), were kindly supplied by Thalassemia Research Center, Institute of Molecular Bioscience, Mahidol University, Salaya Campus, Thailand (30, 31) and conducted under the Animal Ethical Committee of Medical Faculty, Chiang Mai University, Thailand (Reference Number 42/2556). The mice were sacrificed and their livers were collected to determine hepcidin1 (*Hamp1*) and *Atoh8* mRNA expression by qPCR.

2.4. RNA extraction and cDNA synthesis

RNA was extracted from HuH7 cells or HEK293 cells by using TRIzol reagent (Invitrogen, UK). In mice, RNA was extracted from 100 mg of liver by using TRIzol and the genomic DNA was removed by using Illustra RNAspin Mini RNA Isolation Kit (GE Healthcare, Buckinghamshire, UK) according to the manufacturer's protocol. 1 μg of RNA was reverse transcribed into complementary DNA (cDNA) using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, USA).

2.5. Quantitative real-time PCR (qPCR)

2.5.1. In cell culture

The qPCR reactions of cDNA were performed using TaqMan Gene Expression Assay (Applied Biosystems) on the ABI PRISM 7900 HT PCR machine (Applied Biosystems, Paisley, UK) or ABI 7500 fast real-time PCR machine (Applied Biosystems, Paisley, UK) according to the

1 manufacturer's protocol. mRNA expression of *HAMP* (Hs00221783_m1) or *Atoh8*
2 (Hs01031629_m1) was normalized to housekeeping gene *RLP19* (Hs01577060_gH) and
3 expressed as a fold change by using $\Delta\Delta CT$ method (32).

4 **2.5.2. *In mice***

5 The qPCR reactions of cDNA were performed using EXPRESS SYBR® GreenER™ qPCR
6 Supermix Universal Kits (Invitrogen, Carlsbad, CA, USA) on the ABI 7500 real-time PCR
7 machine (Applied Biosystems, Carlsbad, CA, USA) according to the manufacturer's protocol. The
8 primer sequences used in qPCR are presented as follows; *mHamp1* forward:
9 CCTGAGCAGCACCTATC, *mHamp1* reverse: TGCAACAGATACCACACTGGG,
10 *mAtoh8* forward: TCAGCTTCTCCGAGTGTGTG, *mAtoh8* reverse:
11 TAGCCTGTGGCAGGTCACT (25), *mActb* forward: GGTCCACACCCGCCAC, *mActb* reverse:
12 GTCCTTCTGACCCATTCCCA. mRNA expression of *Hamp1* or *Atoh8* was normalized to
13 housekeeping gene β -actin (*Actb*) and expressed as a fold change by using $\Delta\Delta CT$ method (32).

14 **2.6. *Luciferase reporter assays***

15 The luminescence from HuH7 cells or HEK293 cells was detected by using Dual-Luciferase
16 Reporter Assay according to the manufacturer's instructions (Promega, UK) and measured by a
17 luminometer (Promega, UK). Relative luciferase activity was calculated from the ratio of the signal
18 of firefly luciferase to TK-renilla luciferase and expressed as the fold change to the control group.

19 **2.7. *Statistical Analysis***

20 The data are presented as means $\pm$ SD. Data analysis was undertaken by using SPSS program,
21 and statistical significance was determined by using one-way analysis of variance (ANOVA). The
22 p value <0.05 was considered significant.

3. Results

3.1. Blood iron parameters

The blood iron parameters of the pooled human sera: normal, male HbE/ β -thalassemia, female HbE/ β -thalassemia, male β -thalassemia major and female β -thalassemia major were analyzed as shown in the **Table 1**. Serum iron, transferrin saturation, plasma NTBI and plasma ferritin levels in all β -thalassemia patient sera were higher than those in normal serum although plasma hepcidin levels were not different, suggesting that the thalassemia patient sera have iron overload condition.

3.2. Effect of β -thalassemia patient sera on *HAMP* and *Atoh8* expression in HuH7 cells

After 24-hour (60% confluent) grown HuH7 cells were starved in serum-free DMEM medium for 24 hours, HuH7 cells were cultured in DMEM medium supplemented with 20% human sera: normal, male HbE/ β -thalassemia, female HbE/ β -thalassemia, male β -thalassemia major and female β -thalassemia major for 24 hours. Subsequently, *HAMP* and *Atoh8* mRNA expression were detected by qPCR. *HAMP* (**Figure 1A**) and *Atoh8* (**Figure 1B**) mRNA levels and *HAMP* promoter activity (**Figure 2**) in all β -thalassemia serum groups were significantly lower than those in the normal serum group, and there was no difference between genders. Interestingly, our study demonstrated that β -thalassemia patients have not only the decreased *HAMP* expression but also the reduced *Atoh8* expression.

3.3. Hepatic *Hamp1* and *Atoh8* mRNA expression in β -thalassemic mice

Hepatic *Hamp1* (**Figure 3A**) and *Atoh8* (**Figure 3B**) mRNA levels in BKO mice were lower than those in WT mice but significantly in female. However, the *Hamp1* and *Atoh8* mRNA expression were not different between genders.

3.4. Effect of *Atoh8* transfection on *HAMP* expression in HEK293 cells grown in β -thalassemia patient sera

To determine whether *Atoh8* regulates *HAMP* transcription in β -thalassemia, HEK293 cells were transfected with increasing amounts of the ATOH8-FLAG expression plasmid and grown in the β -thalassemia patient sera. The HEK293 cells were transfected with 0.5, 1, 2 and 4 μ g ATOH8-FLAG expression plasmid and grown in DMEM medium containing 20% female HbE/ β -thalassemia serum for 24 hours. The *Atoh8* transfection could significantly induce *Atoh8* mRNA expression (**Figure 4A**) and up-regulate *HAMP* mRNA expression (**Figure 4B**) in the dose-dependent manner at 2 and 4 μ g ATOH8-FLAG expression plasmid. In accordance with endogenous *HAMP* mRNA levels, *HAMP* promoter activity was more sensitive and significantly increased in the dose-dependent manner with 0.5, 1 and 2 μ g ATOH8-FLAG expression plasmid (**Figure 5**). Furthermore, the *Atoh8* transfection could significantly and markedly enhance *HAMP* expression in both endogenous *HAMP* mRNA and *HAMP* promoter activity not only in the female HbE/ β -thalassemia serum group but also in normal, male HbE/ β -thalassemia, male β -thalassemia major and female β -thalassemia major serum group (**Figure 6 and 7**). The empty plasmid (Origen vector) did not effect on *Atoh8* (**Figure 6A**) and *HAMP* (**Figure 6B**) mRNA levels as well as *HAMP* promoter activity (**Figure 7A**) when compared to the untransfected ATOH8-FLAG group. Thus the *Atoh8* transfection could up-regulate the expression of *Atoh8* probably subsequently activating *HAMP* expression.

4. Discussion

The down-regulation of hepcidin expression in β -thalassemic mice (33-38) and the low hepcidin levels in β -thalassemia patients (12-15, 39) have been previously reported. Although our

1 study showed the indifference of hepcidin levels between β -thalassemia patient serum and normal
2 serum as the previous studies (15, 40, 41), HepG2 grown in the medium containing the thalassemia
3 sera revealed the down-regulation of hepcidin expression (28, 40). Interestingly, this study
4 demonstrated that not only hepcidin but also *Atoh8* was down-regulated in β -thalassemia. The
5 decrease of *Atoh8* mRNA levels also related to the reduction of *HAMP* expression, endogenous
6 *HAMP* mRNA and *HAMP* promoter activity, in the HuH7 cells cultured in DMEM medium
7 supplemented with 20% β -thalassemia patient sera for 24 hours. In this condition, erythropoietic
8 regulatory proteins still effect on *HAMP* expression as same as in the patients. According to the
9 suppression of hepatic *Atoh8* and hepcidin expression in the mice under the conditions with an
10 increased erythropoiesis activity (e.g. hemolytic anemia, hypoxia, erythropoietin treatment, and
11 hypotransferrinaemia) (21, 25, 42-46), this study also showed the lower hepatic *Atoh8* mRNA
12 levels related to the decreased hepatic *Hamp1* mRNA levels in β -thalassemic mice. Courselaud
13 and colleagues demonstrated that hepcidin expression varied between genders of mice (47), but
14 not in some study (41) as well as our data *Atoh8* and hepcidin expression in the β -thalassemia
15 patient serum groups and in the β -thalassemic mice were not different between genders. In
16 addition to erythropoietic activity, *Atoh8* expression responded to a change of iron levels. Hepatic
17 *Atoh8* and *Hamp1* mRNA levels were increased in mice fed with an iron supplemented-diet and
18 in mice treated with holo-transferrin, whereas those were decreased in mice fed with an iron
19 deficient-diet (25, 48). Conversely, *Atoh8* and *HAMP* mRNA expression were suppressed in HuH7
20 cells cultured in the medium containing the β -thalassemia patient sera even though their serum
21 iron and transferrin saturation levels are very high. Similarly, in hypotransferrinaemic (HPX) mice
22 with high degree of chronic anemia and liver iron overload, hepatic *Atoh8* and *Hamp1* expression
23 were also down-regulated (21, 25). *Atoh8* mRNA expression was also inhibited in *Hamp1*^{-/-} mice

after PHZ treatment although their serum iron was still high (25, 44). As previously shown, it is likely that the up-regulation of Atoh8 by iron was overridden by the increased erythropoiesis activity similar to the regulation of hepcidin. Therefore, in β -thalassemia Atoh8 expression was suppressed by the increased erythropoiesis activity in a similar manner and direction to hepcidin expression.

Furthermore, Atoh8 expression was also suppressed in *Hamp1*^{-/-} mice after PHZ treatment increasing erythropoiesis activity, suggesting that Atoh8 is an upstream regulator of *Hamp1* (25). In HEK293 cells, Atoh8 could stimulate *HAMP* transcription in two ways, directly via E-boxes and indirectly through increased pSMAD1,5,8 levels (25). In this study, Atoh8 transfection in HEK293 cultured in the medium containing the β -thalassemia patient sera could induce the *HAMP* expression in both endogenous mRNA and promoter activity. It suggested that the down-regulation of Atoh8 expression in β -thalassemia resulted from the increased erythropoietic activity and subsequently led to the decrease of *HAMP* expression. Therefore, in β -thalassemia Atoh8 may be a novel transcriptional regulator of *HAMP*, which is responsive to the erythropoietic activity. This is a new research for therapies and management in β -thalassemia patients.

Conflict of Interests

The authors attest to having no conflicting interests.

References

1. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. *J Biol Chem*. 2001;276(11):7806-10.
2. Atanasiu V, Manolescu B, Stoian I. Hepcidin--central regulator of iron metabolism. *Eur J Haematol*. 2007;78(1):1-10.

3. Krause A, Neitz S, Magert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. *FEBS Lett.* 2000;480(2-3):147-50.
4. Leong WI, Lonnerdal B. Heparin, the recently identified peptide that appears to regulate iron absorption. *J Nutr.* 2004;134(1):1-4.
5. Rossi E. Heparin--the iron regulatory hormone. *Clin Biochem Rev.* 2005;26(3):47-9.
6. Ganz T, Nemeth E. Iron imports. IV. Heparin and regulation of body iron metabolism. *American journal of physiology Gastrointestinal and liver physiology.* 2006;290(2):G199-203.
7. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Heparin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. *Science.* 2004;306(5704):2090-3.
8. McKie AT, Marciani P, Rolfs A, Brennan K, Wehr K, Barrow D, et al. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. *Mol Cell.* 2000;5(2):299-309.
9. Abboud S, Haile DJ. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. *J Biol Chem.* 2000;275(26):19906-12.
10. Donovan A, Brownlie A, Zhou Y, Shepard J, Pratt SJ, Moynihan J, et al. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. *Nature.* 2000;403(6771):776-81.
11. Knutson MD, Oukka M, Koss LM, Aydemir F, Wessling-Resnick M. Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by heparin. *Proceedings of the National Academy of Sciences of the United States of America.* 2005;102(5):1324-8.
12. Kearney SL, Nemeth E, Neufeld EJ, Thapa D, Ganz T, Weinstein DA, et al. Urinary heparin in congenital chronic anemias. *Pediatric blood & cancer.* 2007;48(1):57-63.
13. Nemeth E, Ganz T. Heparin and iron-loading anemias. *Haematologica.* 2006;91(6):727-32.
14. Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G, et al. Liver iron concentrations and urinary heparin in beta-thalassemia. *Haematologica.* 2007;92(5):583-8.
15. Jones E, Pasricha SR, Allen A, Evans P, Fisher CA, Wray K, et al. Heparin is suppressed by erythropoiesis in hemoglobin E beta-thalassemia and beta-thalassemia trait. *Blood.* 2015;125(5):873-80.
16. Meynard D, Kautz L, Darnaud V, Canonne-Hergaux F, Coppin H, Roth MP. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. *Nature genetics.* 2009;41(4):478-81.
17. Ramos E, Kautz L, Rodriguez R, Hansen M, Gabayan V, Ginzburg Y, et al. Evidence for distinct pathways of heparin regulation by acute and chronic iron loading in mice. *Hepatology.* 2011;53(4):1333-41.
18. Wrighting DM, Andrews NC. Interleukin-6 induces heparin expression through STAT3. *Blood.* 2006;108(9):3204-9.
19. Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein heparin. *Nature medicine.* 2007;13(9):1096-101.
20. Tanno T, Porayette P, Sripichai O, Noh SJ, Byrnes C, Bhupatiraju A, et al. Identification of TWSG1 as a second novel erythroid regulator of heparin expression in murine and human cells. *Blood.* 2009;114(1):181-6.

21. Patel N, Masaratana P, Diaz-Castro J, Latunde-Dada GO, Qureshi A, Lockyer P, et al. BMPER protein is a negative regulator of hepcidin and is up-regulated in hypotransferrinemic mice. *J Biol Chem*. 2012;287(6):4099-106.
22. Chou ST, Weiss MJ. Diseased red blood cells topple iron balance. *Nat Med*. 2007;13(9):1020-1.
23. Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. *Nature genetics*. 2014;46(7):678-84.
24. Casanovas G, Vujic Spasic M, Casu C, Rivella S, Strelau J, Unsicker K, et al. The murine growth differentiation factor 15 is not essential for systemic iron homeostasis in phlebotomized mice. *Haematologica*. 2013;98(3):444-7.
25. Patel N, Varghese J, Masaratana P, Latunde-Dada GO, Jacob M, Simpson RJ, et al. The transcription factor ATOH8 is regulated by erythropoietic activity and regulates HAMP transcription and cellular pSMAD1,5,8 levels. *British journal of haematology*. 2014;164(4):586-96.
26. Frazer DM, Wilkins SJ, Darshan D, Badrick AC, McLaren GD, Anderson GJ. Stimulated erythropoiesis with secondary iron loading leads to a decrease in hepcidin despite an increase in bone morphogenetic protein 6 expression. *British journal of haematology*. 2012;157(5):615-26.
27. Singh S, Hider RC, Porter JB. A direct method for quantification of non-transferrin-bound iron. *Anal Biochem*. 1990;186(2):320-3.
28. Weizer-Stern O, Adamsky K, Amariglio N, Levin C, Koren A, Breuer W, et al. Downregulation of hepcidin and haemojuvelin expression in the hepatocyte cell-line HepG2 induced by thalassaemic sera. *British journal of haematology*. 2006;135(1):129-38.
29. Matak P, Chaston TB, Chung B, Srai SK, McKie AT, Sharp PA. Activated macrophages induce hepcidin expression in HuH7 hepatoma cells. *Haematologica*. 2009;94(6):773-80.
30. Jamsai D, Zaibak F, Khongnium W, Vadolas J, Voullaire L, Fowler KJ, et al. A humanized mouse model for a common beta0-thalassemia mutation. *Genomics*. 2005;85(4):453-61.
31. Jamsai D, Zaibak F, Vadolas J, Voullaire L, Fowler KJ, Gazeas S, et al. A humanized BAC transgenic/knockout mouse model for HbE/beta-thalassemia. *Genomics*. 2006;88(3):309-15.
32. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods*. 2001;25(4):402-8.
33. Parrow NL, Gardenghi S, Ramos P, Casu C, Grady RW, Anderson ER, et al. Decreased hepcidin expression in murine beta-thalassemia is associated with suppression of Bmp/Smad signaling. *Blood*. 2012;119(13):3187-9.
34. Weizer-Stern O, Adamsky K, Amariglio N, Rachmilewitz E, Breda L, Rivella S, et al. mRNA expression of iron regulatory genes in beta-thalassemia intermedia and beta-thalassemia major mouse models. *American journal of hematology*. 2006;81(7):479-83.
35. Gardenghi S, Marongiu MF, Ramos P, Guy E, Breda L, Chadburn A, et al. Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. *Blood*. 2007;109(11):5027-35.
36. Adamsky K, Weizer O, Amariglio N, Breda L, Harmelin A, Rivella S, et al. Decreased hepcidin mRNA expression in thalassaemic mice. *Br J Haematol*. 2004;124(1):123-4.
37. De Franceschi L, Daraio F, Filippini A, Carturan S, Muchitsch EM, Roetto A, et al. Liver expression of hepcidin and other iron genes in two mouse models of beta-thalassemia. *Haematologica*. 2006;91(10):1336-42.

38. Breda L, Gardenghi S, Guy E, Rachmilewitz EA, Weizer-Stern O, Adamsky K, et al. Exploring the role of hepcidin, an antimicrobial and iron regulatory peptide, in increased iron absorption in beta-thalassemia. *Annals of the New York Academy of Sciences*. 2005;1054:417-22.
39. Camberlein E, Zanninelli G, Detivaud L, Lizzi AR, Sorrentino F, Vacquer S, et al. Anemia in beta-thalassemia patients targets hepatic hepcidin transcript levels independently of iron metabolism genes controlling hepcidin expression. *Haematologica*. 2008;93(1):111-5.
40. Kemna EH, Kartikasari AE, van Tits LJ, Pickkers P, Tjalsma H, Swinkels DW. Regulation of hepcidin: insights from biochemical analyses on human serum samples. *Blood cells, molecules & diseases*. 2008;40(3):339-46.
41. Fertrin KY, Lanaro C, Franco-Penteado CF, de Albuquerque DM, de Mello MR, Pallis FR, et al. Erythropoiesis-driven regulation of hepcidin in human red cell disorders is better reflected through concentrations of soluble transferrin receptor rather than growth differentiation factor 15. *American journal of hematology*. 2014;89(4):385-90.
42. Frazer DM, Inglis HR, Wilkins SJ, Millard KN, Steele TM, McLaren GD, et al. Delayed hepcidin response explains the lag period in iron absorption following a stimulus to increase erythropoiesis. *Gut*. 2004;53(10):1509-15.
43. Latunde-Dada GO, McKie AT, Simpson RJ. Animal models with enhanced erythropoiesis and iron absorption. *Biochim Biophys Acta*. 2006;1762(4):414-23.
44. Masaratana P, Latunde-Dada GO, Patel N, Simpson RJ, Vulont S, McKie AT. Iron metabolism in hepcidin1 knockout mice in response to phenylhydrazine-induced hemolysis. *Blood Cells Mol Dis*. 2012;49(2):85-91.
45. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. *The Journal of clinical investigation*. 2002;110(7):1037-44.
46. Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S. Suppression of hepcidin during anemia requires erythropoietic activity. *Blood*. 2006;108(12):3730-5.
47. Courselaud B, Troadec MB, Fruchon S, Ilyin G, Borot N, Leroyer P, et al. Strain and gender modulate hepatic hepcidin 1 and 2 mRNA expression in mice. *Blood Cells Mol Dis*. 2004;32(2):283-9.
48. Kautz L, Meynard D, Monnier A, Darnaud V, Bouvet R, Wang RH, et al. Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad7, Id1, and Atoh8 in the mouse liver. *Blood*. 2008;112(4):1503-9.

1 **Table 1** Blood iron parameters of human sera

Blood chemistry	Normal	HbE/T- Male	HbE/T- Female	TM- Male	TM- Female
SI (µg/dl)	52	140	135	161	155
TIBC (µg/dl)	339	148	135	161	155
Transferrin saturation (%)	15.34	94.59	100	100	100
NTBI (µM)	-0.39	7.31	7.77	5.46	4.07
Ferritin (ng/ml)	26.31	1307	1812	2000	1405
Hepcidin (ng/ml)	34.69	42.78	38.08	32.90	47.76

2

Figure legends

Figure 1 Effect of β -thalassemia patient sera on *HAMP* and *Atoh8* mRNA expression in HuH7 cells grown in DMEM medium supplemented with 20% human sera for 24 hours. Relative *HAMP* (A) and *Atoh8* (B) mRNA expression from qPCR analysis were acquired by normalizing *HAMP* mRNA or *Atoh8* mRNA to *RPL19* mRNA. The samples were determined in quadruplicate in two independent experiments. Values are expressed as mean $\pm$ SD derived from a single experiment with four biological replicates for the fold change as compared to the normal serum group. The experiment shown is representative of two similar experiments. * $p < 0.05$ when compared with the normal serum group.

Figure 2 Effect of β -thalassemia patient sera on *HAMP* promoter activity in HuH7 cells co-transfected with *HAMP* reporter plasmid and TK-renilla and grown in DMEM medium supplemented with 20% human sera for 24 hours. Promoter activity was expressed as the relative luciferase activity to the normal serum group. The samples were determined in triplicate. Values are expressed as mean $\pm$ SD for the fold change as compared to the normal serum group. * $p < 0.05$ when compared with the normal serum group.

Figure 3 Hepatic *Hamp1* and *Atoh8* mRNA expression of male (N=5) and female (N=5) mice. Relative *Hamp1* (A) and *Atoh8* (B) mRNA expression in WT and BKO mice from qPCR analysis were acquired by normalizing *Hamp1* mRNA or *Atoh8* mRNA to *Actb* mRNA. Values are expressed as mean $\pm$ SD for the fold change as compared to the WT-male group.

Figure 4 *Atoh8* and *HAMP* mRNA expression in HEK293 cells transfected with (1, 2 and 4 μ g) ATOH8-FLAG expression plasmid and grown in DMEM medium supplemented with 20% female HbE/ β -thalassemia serum for 24 hours. Relative *Atoh8* (A) and *HAMP* (B) mRNA expression from qPCR analysis were acquired by normalizing *Atoh8* mRNA or *HAMP*

mRNA to *RPL19* mRNA. The samples were determined in triplicate. Values are expressed as mean $\pm$ SD for the fold change as compared to the untransfected ATOH8-FLAG group. *p<0.05 when compared with the untransfected ATOH8-FLAG group.

Figure 5 *HAMP* promoter activity in HEK293 cells co-transfected with *HAMP* reporter plasmid, TK-renilla and (0.5, 1 and 2 μ g) ATOH8-FLAG expression plasmid and grown in DMEM medium supplemented with 20% female HbE/ β -thalassemia serum for 24 hours.

Promoter activity was expressed as the relative luciferase activity to the untransfected ATOH8-FLAG group. The samples were determined in triplicate. Values are expressed as mean $\pm$ SD for the fold change as compared to the untransfected ATOH8-FLAG group. *p<0.05 when compared with the untransfected ATOH8-FLAG group.

Figure 6 *Atoh8* and *HAMP* mRNA expression in HEK293 cells transfected with (2 μ g) ATOH8-FLAG expression plasmid or empty plasmid (Origen vector) and grown in DMEM medium supplemented with 20% human sera for 24 hours. Relative *Atoh8* (A) and *HAMP* (B) mRNA expression from qPCR analysis were acquired by normalizing *Atoh8* mRNA or *HAMP* mRNA to *RPL19* mRNA. The samples were determined in triplicate. Values are expressed as mean $\pm$ SD for the fold change as compared to the untransfected ATOH8-FLAG group.

Figure 7 *HAMP* promoter activity in HEK293 cells co-transfected with *HAMP* reporter plasmid, TK-renilla and (0.5 and 1 μ g) ATOH8-FLAG expression plasmid (or Origen vector) and grown in DMEM medium supplemented with 20% human sera (A: Female HbE/ β -thalassemia, B: Normal, C: Male HbE/ β -thalassemia, D: Male β -thalassemia major, D: Female β -thalassemia major) for 24 hours. Promoter activity was expressed as the relative luciferase activity to the untransfected ATOH8-FLAG group. The samples were determined in

- 1 triplicate. Values are expressed as mean $\pm$ SD for the fold change as compared to the untransfected
- 2 ATOH8-FLAG group. *p<0.05 when compared with the untransfected ATOH8-FLAG group.
- 3

Figure 1 Effect of β -thalassemia patient sera on *HAMP* and *Atoh8* mRNA expression in HuH7 cells grown in DMEM medium supplemented with 20% human sera for 24 hours. Relative *HAMP* (A) and *Atoh8* (B) mRNA expression from qPCR analysis were acquired by normalizing *HAMP* mRNA or *Atoh8* mRNA to *RPL19* mRNA. The samples were determined in quadruplicate in two independent experiments. Values are expressed as mean $\pm$ SD derived from a single experiment with four biological replicates for the fold change as compared to the normal serum group. The experiment shown is representative of two similar experiments. * $p < 0.05$ when compared with the normal serum group.

Figure 2 Effect of β -thalassemia patient sera on *HAMP* promoter activity in HuH7 cells co-transfected with *HAMP* reporter plasmid and TK-renilla and grown in DMEM medium supplemented with 20% human sera for 24 hours. Promoter activity was expressed as the relative luciferase activity to the normal serum group. The samples were determined in triplicate. Values are expressed as mean $\pm$ SD for the fold change as compared to the normal serum group. * $p < 0.05$ when compared with the normal serum group.

Figure 3 Hepatic *Hamp1* and *Atoh8* mRNA expression of male (N=5) and female (N=5) mice.

Relative *Hamp1* (A) and *Atoh8* (B) mRNA expression in WT and BKO mice from qPCR analysis were acquired by normalizing *Hamp1* mRNA or *Atoh8* mRNA to *Actb* mRNA. Values are expressed as mean $\pm$ SD for the fold change as compared to the WT-male group.

Figure 4 *Atoh8* and *HAMP* mRNA expression in HEK293 cells transfected with (1, 2 and 4 µg) ATOH8-FLAG expression plasmid and grown in DMEM medium supplemented with 20% female HbE/ β-thalassemia serum for 24 hours. Relative *Atoh8* (A) and *HAMP* (B) mRNA expression from qPCR analysis were acquired by normalizing *Atoh8* mRNA or *HAMP* mRNA to *RPL19* mRNA. The samples were determined in triplicate. Values are expressed as mean±SD for the fold change as compared to the untransfected ATOH8-FLAG group. *p<0.05 when compared with the untransfected ATOH8-FLAG group.

Figure 5 *HAMP* promoter activity in HEK293 cells co-transfected with *HAMP* reporter plasmid, TK-renilla and (0.5, 1 and 2 µg) ATOH8-FLAG expression plasmid and grown in DMEM medium supplemented with 20% female HbE/ β -thalassemia serum for 24 hours. Promoter activity was expressed as the relative luciferase activity to the untransfected ATOH8-FLAG group. The samples were determined in triplicate. Values are expressed as mean $\pm$ SD for the fold change as compared to the untransfected ATOH8-FLAG group. * p <0.05 when compared with the untransfected ATOH8-FLAG group.

Figure 6 *Atoh8* and *HAMP* mRNA expression in HEK293 cells transfected with (2 µg) ATOH8-FLAG expression plasmid or empty plasmid (Origen vector) and grown in DMEM medium supplemented with 20% human sera for 24 hours. Relative *Atoh8* (A) and *HAMP* (B) mRNA expression from qPCR analysis were acquired by normalizing *Atoh8* mRNA or *HAMP* mRNA to *RPL19* mRNA. The samples were determined in triplicate. Values are expressed as mean±SD for the fold change as compared to the untransfected ATOH8-FLAG group.

Figure 7 *HAMP* promoter activity in HEK293 cells co-transfected with *HAMP* reporter plasmid, TK-renilla and (0.5 and 1 µg) ATOH8-FLAG expression plasmid (or Origen vector) and grown in DMEM medium supplemented with 20% human sera (A: Female HbE/β-thalassemia, B: Normal, C: Male HbE/β-thalassemia, D: Male β-thalassemia major, E: Female β-thalassemia major) for 24 hours. Promoter activity was expressed as the relative luciferase activity to the untransfected ATOH8-FLAG group. The samples were determined in triplicate. Values are expressed as mean±SD for the fold change as compared to the untransfected ATOH8-FLAG group. *p<0.05 when compared with the untransfected ATOH8-FLAG group.